16:03 EST Day One backs FY26 revenue view $225M-$250M, consensus $236.56M
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DAWN:
- DAWN Upcoming Earnings Report: What to Expect?
- Day One Biopharmaceuticals price target lowered to $24 from $34 at TD Cowen
- Day One Biopharmaceuticals: Buy Rating Reiterated as Updated Ojemda Forecasts and DCF Support Attractive Valuation Despite Lowered Price Target
- Day One Biopharmaceuticals reinstated with a Buy at TD Cowen
- Day One Biopharmaceuticals: Ojemda Outperformance and Advancing Pipeline Support Overweight Rating